Evidence map›Paper›PMID 39567515›Full record

ReviewNPJ Parkinson's disease2024

Accelerating Parkinson's Disease drug development with federated learning approaches.

Amit Khanna, Jamie Adams, Chrystalina Antoniades, Bastiaan R Bloem, Camille Carroll, Jesse Cedarbaum, Joshua Cosman, David T Dexter, Marissa F Dockendorf, Jeremy Edgerton and 25 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in NPJ Parkinson's disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Developing digital health technologies for frontotemporal degeneration.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

35 authors.

Amit KhannaNeuroscience Development, Novartis AG, Basel, Switzerland.
Jamie AdamsDepartment of Neurology and Center for Health and Technology, University of Rochester, Rochester, NY, USA.
Chrystalina AntoniadesNeuroMetrology Lab, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0002-1192-3834
Bastiaan R BloemRadboud University Medical Centre, Nijmegen, The Netherlands.ORCID http://orcid.org/0000-0002-6371-3337
Camille CarrollTranslational and Clinical Research Institute, Newcastle University, Newcastle-upon-Tyne, UK.
Jesse CedarbaumDepartment of Neurology, Yale School of Medicine, New Haven, CT, 06511, USA.
Joshua CosmanAbbVie Pharmaceuticals, North Chicago, IL, USA.ORCID http://orcid.org/0000-0003-3320-4053
David T DexterParkinson's UK, 50 Broadway, London, UK.ORCID http://orcid.org/0000-0002-7974-9588
Marissa F DockendorfMerck & Co., Inc., Rahway, NJ, USA.ORCID http://orcid.org/0000-0002-6341-0221
Jeremy EdgertonBiogen Inc, Cambridge, MA, USA.
Laura GaetanoNeuroscience Development, Novartis AG, Basel, Switzerland.
Erkuden GoikoetxeaUCB Pharmaceuticals, Leuven, Belgium.
Derek HillPanoramic Digital Health, Grenoble, France.
Fay HorakOregon Health and Science University, Portland, USA.
Elena S IzmailovaKoneksa Health, One World Trade Center, 285 Fulton St., New York, NY, USA.
Tairmae KangarlooTakeda Pharmaceuticals, Cambridge, MA, USA.
Dina KatabiDepartment of Electrical Engineering and Computer Science, Massachusetts Institute of Technology, Cambridge, MA, USA.
Catherine KopilThe Michael J. Fox Foundation for Parkinson's Research, New York, NY, USA.
Michael LindemannF. Hoffmann-La Roche Ltd, Basel, Switzerland.ORCID http://orcid.org/0000-0003-1010-3890
Jennifer MammenUniversity of Massachusetts, Dartmouth, College of Nursing and Health Sciences, Dartmouth, USA.ORCID http://orcid.org/0000-0001-7858-9183
Kenneth MarekInstitute for Neurodegenerative Disorders, New Haven, CT, USA.
Kevin McFarthingParkinson's research advocate, Oxford, UK.
Anat MirelmanFaculty of Medicine and Sagol School of Neuroscience, Tel Aviv University and Tel Aviv Medical Center, Tel Aviv-Yafo, Israel.
Martijn MullerCritical Path Institute for Parkinson's Disease Consortium, Critical Path Institute, 1840 E River Rd, Suite 100, Tucson, AZ, 85718, USA.
Gennaro PaganoF. Hoffmann-La Roche, Basel, Switzerland.ORCID http://orcid.org/0000-0002-6247-8988
M Judith PeterschmittResearch and Development, Sanofi, Cambridge, MA, USA.
Jie RenMerck & Co., Inc., Rahway, NJ, USA.
Lynn RochesterTranslational and Clinical Research Institute, Newcastle University, Newcastle-upon-Tyne, UK.
Sakshi SardarCritical Path Institute for Parkinson's Disease Consortium, Critical Path Institute, 1840 E River Rd, Suite 100, Tucson, AZ, 85718, USA.
Andrew SiderowfUniversity of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0002-1750-7698
Tanya SimuniFeinberg School of Medicine, Northwestern University, Chicago, IL, USA.ORCID http://orcid.org/0000-0002-2347-1644
Diane StephensonCritical Path Institute for Parkinson's Disease Consortium, Critical Path Institute, 1840 E River Rd, Suite 100, Tucson, AZ, 85718, USA.
Christine Swanson-FischerNational Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA.
John A WagnerKoneksa Health, One World Trade Center, 285 Fulton St., New York, NY, USA.
Graham B JonesData, Design and Clinical Innovation, Novartis Pharmaceuticals, Cambridge, MA, USA. graham.jones@novartis.com.ORCID http://orcid.org/0000-0003-2195-3567

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parkinson's Disease is a progressive neurodegenerative disorder afflicting almost 12 million people. Increased understanding of its complex and heterogenous disease pathology, etiology and symptom manifestations has resulted in the need to design, capture and interrogate substantial clinical datasets. Herein we advocate how advances in the deployment of artificial intelligence models for Federated Data Analysis and Federated Learning can help spearhead coordinated and sustainable approaches to address this grand challenge.

Identifiers

PMID39567515
PMCPMC11579312

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.